Outbreak of invasive aspergillosis in heart transplant recipients: The role of screening computed tomography scans in asymptomatic patients and universal antifungal prophylaxis

Dima Kabbani¹,² | Livia Goldraich³,⁴ | Heather Ross³ | Coleman Rotstein¹ | Shahid Husain¹

¹Division of Infectious Diseases, University of Toronto, University Health Network, Toronto General Hospital, Toronto, ON, Canada
²Division of Infectious Diseases, University of Alberta, Edmonton, AB, Canada
³Division of Cardiology, University Health Network, University of Toronto, Toronto, ON, Canada
⁴Division of Cardiology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil

Correspondence
Shahid Husain, MD, Multi-Organ Transplant Program, Division of Infectious Diseases, Toronto General Hospital, University Health Network and University of Toronto, Toronto, ON, Canada. Email: shahid.husain@uhn.ca

Abstract

Background: Delays in diagnosing pulmonary invasive aspergillosis (IA), a significant cause of morbidity and mortality among heart transplant recipients (HTRs), may impact on successful treatment. The appropriate screening strategy for IA in these patients remains undefined, particularly in the setting of nosocomial outbreaks. We describe our experience employing chest computed tomography (CT) scans as a screening method for IA. In addition, we comment on antimicrobial prophylaxis in HTRs in the setting of an outbreak.

Methods: Screening CT scans of the chest and serum galactomannan (GM) were performed in HTRs during an outbreak that followed the index case of IA. Abnormal CT findings prompted a diagnostic workup. Antimicrobial prophylaxis for new transplant recipients included intravenous micafungin while hospitalized, followed by outpatient inhaled amphotericin B for up to 3 months.

Results: During a 10-month period, five cases of IA were identified among HTRs. Two additional asymptomatic patients were diagnosed with IA among 15 asymptomatic HTRs who underwent screening chest CT scans. Among the five cases of IA in HTRs, two of five (40%) had a partial response and the other three failed voriconazole therapy. Complete response to voriconazole therapy assessed at 12 weeks was achieved in these two asymptomatic HTRs diagnosed via screening CTs. Serum GM was positive only in one of the symptomatic cases. The negative predictive value of CT scans was 100% (95% confidence interval, 71.5%-100%).

Conclusions: In an outbreak setting, screening CT scans of the chest may aid in early detection of asymptomatic HTRs with IA and improve outcome.

KEYWORDS
heart transplant, imaging, invasive aspergillosis, outbreak, screening

INTRODUCTION

Pulmonary invasive aspergillosis (IA) remains a significant cause of morbidity and mortality in solid organ transplantation (SOT). IA has been reported in 1.6%-14% of heart transplant recipients (HTRs), with most the cases occurring within the first 3 months post transplant.¹ Nosocomially acquired IA has been noted in setting of outbreaks, and has been linked to construction work within the hospital settings or surroundings. Delay in establishing an early diagnosis remains a major impediment to the successful treatment of IA. Data in hematological
malignancies suggest that computed tomography (CT) scans of the chest may detect the diseases earlier than serum galactomannan (GM). However, the appropriate screening strategy for IA in the setting of an outbreak in HTRs remains undefined.

From February to October 2013, an unusually high number of IA cases were noted in HTRs at our institution. The present retrospective report describes our experience utilizing CT scans of the chest, as an early detection screening method for IA in asymptomatic HTRs in the setting of an institutional outbreak. In addition, we describe the antimicrobial prophylaxis undertaken and the outcomes at the end of prophylactic period.

2 | METHODS

This retrospective cohort study evaluated all consecutive HTRs between January 2013 and September 2014. Institutional ethics approval was obtained. As a part of the outbreak investigation, from February to October 2013, five heart transplant recipients (HTRs) were diagnosed with invasive aspergillosis (IA). An outbreak was declared and two interventions were undertaken simultaneously. In HTRs transplanted between February and October of 2013, serum galactomannan (GM) and screening chest computed tomography (CT) scans were performed, and if the CT scan of the chest was normal, they were started on inhaled amphotericin (Inh Ampho) for 3 months. From October 2013 onward, all new HTRs were started on micafungin 50 mg intravenously daily while the patients were hospitalized, followed by inhaled amphotericin 20 mg twice a day for 3 months. 1: Screening CT, 2: Antifungal prophylaxis

TABLE 1 Clinical characteristics and outcomes of invasive aspergillosis cases among the outbreak in heart transplant recipients

| Age, years/ gender | Days from transplant | HF etiology | Bridge-to-transplant LVAD | Status at transplant | Diagnostic vs screening CT | Symptoms |
|--------------------|----------------------|-------------|--------------------------|-----------------------|---------------------------|----------|
| 43M                | 7                    | Congenital  | No                       | Home                  | Diagnostic                | Respiratory failure requiring intubation |
| 51M                | 79                   | Idiopathic  | No                       | ICU on inotropes       | Diagnostic                | Cough, dyspnea and chest pain             |
| 58M                | 88                   | Idiopathic  | No                       | Home                  | Diagnostic                | Cough, dyspnea and chest pain             |
| 53F                | 70                   | Myocarditis | No                       | Home                  | Diagnostic                | Cough, dyspnea, chest pain and fever      |
| 60M                | 87                   | Ischemic    | Yes                      | Home                  | Diagnostic                | Cough and fever                          |
| 57M                | 67                   | Ischemic    | No                       | Home                  | Screening                 | No                                   |
| 63M                | 100                  | Idiopathic  | Yes                      | Home                  | Screening                 | No                                   |

*Death caused by intracranial hemorrhage related to treatment-induced thrombocytopenia.
M, male; HF, heart failure; LVAD, left ventricular assist device; CT, computerized tomography; BAL, bronchoalveolar lavage; GM, galactomannan; FNA, fine-needle aspiration; ICU, intensive care unit; IA, invasive aspergillosis; F, female; PCR, polymerase chain reaction.
environmental sampling of air in several locations and equipment was conducted by the Infection Prevention and Control Team at our institution. The antimicrobial prophylaxis implemented during the outbreak following heart transplantation for all new HTRs from October 2013 onward was micafungin 50 mg intravenously daily while the patients were hospitalized, followed by inhaled amphotericin (AmB) 20 mg twice a day for 3 months. For recipients transplanted between February and October of 2013, serum GM and screening chest CT scans were performed; and if the CT scan of the chest was normal, they were started on inhaled AmB for 3 months. Abnormal CT findings prompted a diagnostic workup including bronchoscopy with cultures and GM, and/or biopsy. In addition, a follow-up chest CT scan was performed on patients who did not tolerate prophylaxis.

IA was defined according to clinical and radiological criteria established by the European Organization for Research and Treatment of Cancer (EORTC)/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (MSG) and the International Society for Heart and Lung Transplantation (ISHLT) Infectious Diseases Council Working Group Definitions criteria for invasive fungal pneumonia.1,2 Response to treatment was characterized by the MSG and the EORTC Consensus Criteria.3 The proportions of IA cases identified by chest CT among screened individuals were accounted.

3 | RESULTS

Thirty-eight heart transplantations were performed during the study period (Figure 1). Mean age at transplant was 54 ± 13 years and 79.5% were male. Approximately half of them were bridged to transplant with mechanical circulatory support devices. All cases received low-dose induction therapy with anti-thymocyte globulin (<3 mg/kg total dose) and subsequent triple therapy immunosuppression with prednisone, tacrolimus, and mycophenolate mofetil. For the 10-month period (February–October 2013), five cases of proven/probable IA were identified among HTRs (median time from transplant to diagnosis was 79 days). Of those, three of five HTRs with IA died (Table 1).

A total of 15 recipients underwent screening chest CT scans (Figure 1). During the screening period, a median of two scans per patient were performed. The median time from transplantation to initial chest CT was 164 days (IQR 115–216), 292 days (IQR 248–335) for second CT, and 366 days (IQR 348–388) for third CT. Four (27%) HTRs had abnormal initial CT scans, two of which were diagnosed with IA (Figure 2A and B). Both IA cases had the diagnosis of IA established after imaging screening although they were asymptomatic. The other two HTRs with abnormal CT chest were diagnosed with post-transplant lymphoproliferative disease and coronavirus lower respiratory tract infection respectively. The two asymptomatic cases of IA that were identified by screening had complete response to therapy at 12 weeks of treatment with voriconazole compared to partial or failure of therapy in the five index cases (Table 1). Serum GM was performed on 30 HTRs; it was positive only in one of five symptomatic cases. Bronchoalveolar lavage GM was performed in five of the symptomatic HTRs with IA and was positive in four patients. Of a total of 28 who received inhaled AmB, 53% had to discontinue treatment before the end of 3 months because of side effects. None of the HTRs who had normal CTs and subsequently received prophylaxis developed IA. No additional cases of IA were identified.

| CT findings                                      | Method of diagnosis | Aspergillus culture | BAL GM | Treatment          | Outcome at 12 weeks                  |
|-------------------------------------------------|---------------------|---------------------|--------|--------------------|--------------------------------------|
| Dense bilateral consolidation                    | BAL GM              | Negative            | Positive 1.98 | Voriconazole   | Treatment failure and non-IA-related death³ |
| Left lower lobe consolidation and middle lobe nodule with pleural effusion | BAL GM + sputum culture | Aspergillus terreus | Positive 3.85 | Voriconazole and micafungin | Treatment failure and IA-related death |
| Bilateral nodules, masses and consolidations     | BAL GM + BAL culture | Aspergillus fumigatus | Positive 1 | Voriconazole followed by posaconazole | Partial response |
| Mass-like opacity in lower lobe with surrounding ground glass and numerous scattered parenchymal small nodules | BAL GM + CT-guided biopsy (mucormycosis identified by PCR from lung biopsy) | Negative | Positive 1.6 | Voriconazole and amphotericin | Treatment failure and IA and mucormycosis related death |
| Mass-like opacity in the superior segment of the right lower lobe | FNA and BAL culture | Aspergillus fumigatus | Negative | Voriconazole | Partial response |
| Multiple bilateral hazy nodules                  | CT-guided biopsy    | Aspergillus nidulans | Not done | Voriconazole     | Complete response                     |
| Left upper lobe nodule                          | CT-guided biopsy    | Aspergillus fumigatus | Not done | Voriconazole     | Complete response                     |
identified since the screening and prophylactic measures were insti-
tuted (Figure 1).

Air and environmental sampling investigations of potential com-
mon pre- and post-admission exposure links during this outbreak
failed to reveal a common environmental source of infection, although
it was thought that the construction around the hospital might have
played a role.

4 | DISCUSSION

Our study underscores the high mortality rate (43%, 3/7) associated
with IA in HTRs in an outbreak setting. Munoz et al\(^1\) described a
similarly adverse outcome, with two deaths of three patients af-
fected during an outbreak of IA in a major heart surgery unit. In
addition, similar to other SOT studies,\(^1\) the sensitivity of serum
GM in detecting cases of IA was poor; only one HTR with IA had
a positive serum GM. Hence, we could not rely on the latter as a
screening tool, and performed low radiation dose CT scans of the
chest on asymptomatic HTRs. This helped to identify two asympto-
matic HTRs with IA, who achieved complete response to therapy at
12 weeks, as compared to partial response or failure to therapy in
the rest of cohort, including three deaths. Although this screening
strategy might be costly and expose patients to increased radiation,
it helped identify asymptomatic HTRs early in the course of disease.
The concept of early diagnosis and improved outcomes has been
shown in patients with hematological malignancy and invasive fun-
gal infection.\(^2,6\) This strategy also helped in following patients who
did not tolerate prophylaxis because of side effects, and ensuring
that these HTRs did not develop IA.

Our study possesses several limitations. Despite our limited
single-center, retrospective, small cohort, and the absence of a con-
trol group, we have shown that, in an outbreak setting, early diagno-
sis of IA by CT scanning of the chest may be an effective screening
strategy in HTRs and improve outcomes. The negative predictive
value of CT scans in diagnosis IA was 100%; 95% confidence in-
terval (71.5%-100%). Based on our experience during an outbreak
of aspergillosis, we propose a combination of screening thoracic
CT scans on patients transplanted during the same period as the
index cases, in addition to universal prophylaxis on all new HTRs.
However, since this study represents the experience of a single cen-
ter in the context of an outbreak, larger studies will be needed be-
fore our strategy can be recommended for generalization.

5 | CONCLUSIONS

The best screening and prophylaxis strategies in the setting of an
outbreak of IA in HTRs remain unclear. CT scans of the chest as a
screening procedure prior to the institution of antifungal prophy-
laxis may aid in the early detection of IA, which is associated with
better outcomes.

DISCLOSURES

The authors have no conflicts of interest to disclose.

REFERENCES

1. Munoz P, Ceron I, Valero M, et al. Invasive aspergillosis among heart
transplant recipients: A 24-year perspective. J Heart Lung Transplant.
2014;33:278-288.
2. Weisser M, Rausch C, Droll A, et al. Galactomannan does not precede
major signs on a pulmonary computerized tomographic scan suggestive
of invasive aspergillosis in patients with hematological malignancies.
Clin Infect Dis. 2005;41:1143-1149.
3. Husain S, Mooney M, Danziger-Isakov L, et al. A 2010 working formula-
tion for the standardization of definitions of infections in cardiothoracic
transplant recipients (consensus document). J Heart Lung Transplant.
2011;30:361-374.
4. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of inva-
sive fungal disease from the European Organization for Research and
Treatment of Cancer/Invasive Fungal Infections Cooperative

FIGURE 2 (A and B) Computed
tomography scan findings in two heart
transplant recipients diagnosed with
invasive aspergillosis: (A) Multiple bilateral
hazy nodules and left-sided pleural
effusion, and (B) left upper lobe nodule.
Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-1821.

5. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47:674-683.

6. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15:139-147.

How to cite this article: Kabbani D, Goldraich L, Ross H, Rotstein C, Husain S. Outbreak of invasive aspergillosis in heart transplant recipients: The role of screening computed tomography scans in asymptomatic patients and universal antifungal prophylaxis. Transpl Infect Dis. 2018;20:e12808. https://doi.org/10.1111/tid.12808